Adult Dosing
Corticosteroid-responsive dermatoses
- Apply a small quantity of lotion and rub gently into the affected area bid-tid; discontinue therapy when control is achieved
- Alt: Apply tape q12-24 hrs to clean, dry skin; Alt: Gently rub a small quantity of the cream into the affected area qd-qid, depending on severity of the condition; for moist lesions, apply cream bid-tid
Note:
- Avoid using lotion with occlusive dressings unless directed by a clinician
- Occlusive dressings may be required for the management of psoriasis or recalcitrant conditions
- Recommended replacement of the tape q12 hrs; but if the tape is well tolerated and adheres satisfactorily, it may be left in place for 24 hrs
- On development of an infection, discontinue use of tape and other occlusive dressings and institute appropriate antimicrobial therapy
- Consider reassessment of diagnosis if no improvement is seen within 2 wks
Pediatric Dosing
Corticosteroid-responsive dermatoses
- Apply a small quantity of lotion and rub gently into the affected area bid-tid; discontinue therapy when control is achieved
- Alt: Apply tape q12-24 hrs to clean, dry skin; Alt: Gently rub a small quantity of the cream into the affected area qd-qid, depending on the severity of the condition; for moist lesions, apply cream bid-tid
Note:
- Topical corticosteroids in pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen; chronic therapy may interfere with the growth and development of pediatric patients
- Avoid using lotion with occlusive dressings unless directed by a clinician
- Occlusive dressings may be required for the management of psoriasis or recalcitrant conditions
- Recommended replacement of the tape q12 hrs; but if the tape is well tolerated and adheres satisfactorily, it may be left in place for 24 hrs
- On development of an infection, discontinue use of tape and other occlusive dressings and institute appropriate antimicrobial therapy
- Consider reassessment of diagnosis if no improvement is seen within 2 wks
[Outline]
See Supplemental Patient Information
- Reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing syndrome, hyperglycemia, and glucosuria may occur due to systemic absorption of topical corticosteroids
- Application of the more potent steroids over large surface areas, prolonged use, and to areas under occlusion add on to the systemic absorption. Monitor patients periodically for evidence of HPA axis suppression. Discontinue the drug, reduce the frequency of application, or substitute with a less potent steroid if HPA axis suppression is noted
- On discontinuation of topical corticosteroids, there is a prompt and complete recovery of HPA axis function. Signs and symptoms of steroid withdrawal may occur, indicating supplemental systemic corticosteroids
- Pediatric patients may be more susceptible to systemic toxicity, including HPA axis suppression, Cushing syndrome, and intracranial hypertension, as proportionally larger amounts of topical corticosteroids are absorbed. Limit the use to the least amount compatible with an effective therapeutic regimen
- May cause local skin adverse reactions; discontinue the drug and institute appropriate therapy
- Discontinue topical corticosteroid application and institute appropriate therapy if irritation develops
- Appropriate antifungal or antibacterial agent should be instituted if concomitant dermatologic infections occur. Temporarily discontinue therapy until the infection has been adequately controlled
Cautions: Use cautiously in
- Skin infections
- Pediatric patients
Supplemental Patient Information
- Instruct patients to use this medication for external use only and to avoid contact with the eyes. Advise patients not to use it on the face, underarms, or groin areas unless directed by their physician
- Advise patients not to bandage, cover or wrap the treated skin area unless directed by their physician
- Inform patients to promptly contact their physician if no response is seen within 14 days of therapy
- Instruct patients to promptly report any signs of local adverse reactions, particularly under occlusive dressing
- Advise parents of pediatric patients not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings
Pregnancy Category:C
Breastfeeding: Flurandrenolide has not been evaluated during breastfeeding. Short-term application of topical corticosteroids is not expected to pose a risk to the breastfed infant by passage into breastmilk. Use of the least potent drug on the smallest area of the mother's skin is recommended. Ensure that the infant's skin does not come into direct contact with the areas treated with this drug. Use of lower potency corticosteroids and water-miscible cream products on the nipple or areola is recommended. Any topical corticosteroid should be wiped off thoroughly prior to nursing if it is applied to the nipple or areola. This information is (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 18 August 2011). Manufacturer advises caution when administered to nursing mothers.
Pricing data from www.DrugStore.com in U.S.A.
- Cordran 4 MCG/SQCM TAPE [Box] (WATSON LABS)
1 sqcm = $187.2
3 sqcm = $535.16 - Cordran 4 MCG/SQCM TAPE [Box] (WATSON LABS)
1 sqcm = $87.99
3 sqcm = $231.79
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
